News
New GLP-1 weight-loss drugs are changing obesity treatment in India with promising health benefits. Dr. Ambrish Mithal, India's top endocrinologist, in an episode of Booked, highlights the impact of ...
Plain Facts compilation, we present to you data-based insights, with easy-to-read charts, to help you delve deeper into the ...
A cyberattack on Synnovis has been linked to a patient's death at King's College Hospital, marking a serious hacking ...
So could you add weight to your portfolio by taking a slice of Eli Lilly, the US maker of Mounjaro, which is now being ...
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
14h
Zacks Investment Research on MSNNVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...
Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...
1d
Health and Me on MSNEli Lilly’s Mounjaro Kwikpen Gets Indian Approval For Diabetes And Weight LossIndia approves Eli Lilly’s Mounjaro KwikPen, a once-weekly injection for type 2 diabetes and obesity, offering dual hormone ...
The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and ...
Mounjaro is one of the bestselling weight loss drugs. See what your options are if you want to invest in Mounjaro stock.
There are growing concerns about the side effects caused by weight loss injections such as Ozempic, Wegovy and Mounjaro.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results